title: Establishing an Indicator of Hypokalemia in Patients Receiving Anti-Epidermal Growth Factor Receptor Antibodies.
abstract: Risk factors for hypokalemia were analyzed in patients who received anti-epidermal growth factor receptor monoclonal antibodies (anti-EGFR MoAbs) at Gifu Municipal Hospital between February 2010 and March 2013. Subjects were 51 patients (27 men and 24 women) with the median age (interquartile range) of 66 (63-72) years. The study period started from the initiation of anti-EGFR MoAbs administration and ended 4 weeks after administration was completed. Patients were categorized into the side effect group if both minimum serum potassium (Min S-K) grade and b grade (pre-treatment S-K grade-Min S-K grade) were B1; otherwise, they were placed into the no side effect group. Univariate analysis for factors to prevent the side effect identified the "concomitant use of hyperkalemia-inducing drugs" to be statistically significant (p=0.010). Multivariate analysis was conducted on factors with a p value of <0.25 in the univariate analysis and on "concomitant use of hyperkalemia-inducing drugs," which was likely to clinically affect S-K decrease, although its p value was >0.25. It showed that "concomitant use of hyperkalemia-inducing drugs" was a significant risk-prevention factor (odds ratio: 0.138, 95% confidence interval[CI]: 0.033-0.581, p=0.007). In conclusion, "concomitant use of hyperkalemia-inducing drugs" is a factor associated with preventing hypokalemia accompanying anti-EGFR MoAbs administration.
authors.affiliation: Dept. of Pharmacy,Gifu Municipal Hospital.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yasuda
authors.forename: Tomoya
authors.initials: T
authors.lastname: Tachi
authors.forename: Michi
authors.initials: M
authors.lastname: Umeda
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Osawa
authors.forename: Teppei
authors.initials: T
authors.lastname: Makino
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Nagaya
authors.forename: Akihide
authors.initials: A
authors.lastname: Koda
authors.forename: Eriko
authors.initials: E
authors.lastname: Setta
authors.forename: Koji
authors.initials: K
authors.lastname: Matsui
authors.forename: Takuo
authors.initials: T
authors.lastname: Nishina
authors.forename: Makoto
authors.initials: M
authors.lastname: Yamada
authors.forename: Chitoshi
authors.initials: C
authors.lastname: Goto
authors.forename: Hitomi
authors.initials: H
authors.lastname: Teramachi
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D066246:ErbB Receptors / Q000276:immunology*; D005260:Female; D006801:Humans; D007008:Hypokalemia / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012307:Risk Factors
chemical_list: D000911:Antibodies, Monoclonal; C512478:EGFR protein, human; D066246:ErbB Receptors